Hong Kong Stocks Midday Review: Hang Seng Index Falls 0.95% in Morning Session, PCB Concept Stocks Rise Against the Trend

Stock News10-20

The Hang Seng Index dropped 0.95%, or 229 points, to 23,956, while the Hang Seng Tech Index fell 1.21%, according to Zhitong Finance APP. Morning turnover in Hong Kong stocks reached HK$102.1 billion.

PCB concept stocks led the gains. The third-quarter earnings previews for the PCB supply chain have been released in batches, and the price-pass-through logic is expected to be validated. Victory Giant Technology (Huizhou) Co., Ltd. (ASX: 02476) rose 7%; Kingboard Laminates (ASX: 01888) rose 4%; Guanghe Technology (ASX: 01989) rose 2%.

Wuxi Biologics (Cayman) Inc (ASX: 02269) rose 5% after its Wuxi Mashan facility successfully passed an on-site GMP inspection by the U.S. FDA.

Multiple positive factors ignited the physical AI sector, with 51WORLD (ASX: 06651) surging over 26%. OMNIVISION (ASX: 00501) rose more than 7% after proposing to repurchase up to RMB 500 million of A-shares, with its analog and display businesses continuing to grow. Hansoh Pharma (ASX: 03692) rose over 7% after signing another ADC deal with Roche, with potential milestone payments exceeding US$15 billion. LDROBOT (ASX: 01236) rose more than 6% after acquiring European high-end garden equipment brand SABO, accelerating its European market layout. UBTECH Robotics (ASX: 09880) rose over 8% after leading the drafting and participating in the compilation of the first batch of six national standards for humanoid robots, with its full-size embodied humanoid robots ramping up production. LINGYI ITECH (ASX: 01688) rose more than 5% after the iPhone Duo sold out rapidly on its first sale, as the company's physical AI enters a fast track of development. SEER TECH (ASX: 06106) rose over 12% as Open AI expands into robot research and development, with the company's robot brain business enjoying significant advantages. GenFleet Therapeutics-B (ASX: 02595) rose another 7% after GFH375 entered two monotherapy registrational Phase III trials for previously treated KRAS G12D.

GPIXEL (ASX: 03277) at one point fell more than 20% to a new listing low, down 14% at midday, as over 30 million restricted shares became eligible for trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment